Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes

As of June 10th 2020 about 7.2 million individuals have tested positive for, and more than 410,000 have died due to COVID-19. In this review we outline the pathophysiology that underpins the potential use of anti-rheumatic therapies for severe COVID-19 infection and summarize the current evidence re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kastritis, Efstathios, Kitas, George D., Vassilopoulos, Dimitrios, Giannopoulos, Georgios, Dimopoulos, Meletios A., Sfikakis, Petros P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353833/
https://www.ncbi.nlm.nih.gov/pubmed/32654078
http://dx.doi.org/10.1007/s00296-020-04629-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353833/
https://www.ncbi.nlm.nih.gov/pubmed/32654078
http://dx.doi.org/10.1007/s00296-020-04629-x

Ejemplares similares